{"organizations": [], "uuid": "c13274fa2f7de794a2e26ad2c8096238058fa1dd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-delmar-pharmaceuticals-presents-po/brief-delmar-pharmaceuticals-presents-positive-updates-on-2-ongoing-clinical-trials-with-val-083-for-treatment-of-mgmt-unmethylated-gbm-idUSASC09W5X", "country": "US", "domain_rank": 408, "title": "BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T21:07:00.000+03:00", "replies_count": 0, "uuid": "c13274fa2f7de794a2e26ad2c8096238058fa1dd"}, "author": "", "url": "https://www.reuters.com/article/brief-delmar-pharmaceuticals-presents-po/brief-delmar-pharmaceuticals-presents-positive-updates-on-2-ongoing-clinical-trials-with-val-083-for-treatment-of-mgmt-unmethylated-gbm-idUSASC09W5X", "ord_in_thread": 0, "title": "BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "treatment of mgmt-unmethylated gbm reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "delmar pharmaceuticals inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 6:08 PM / Updated 7 minutes ago BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM Reuters Staff 1 Min Read \nApril 17 (Reuters) - DelMar Pharmaceuticals Inc: \n* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM \n* DELMAR PHARMACEUTICALS - NO DOSE-LIMITING TOXICITIES HAVE BEEN REPORTED FOLLOWING TREATMENT WITH MULTIPLE CYCLES OF VAL-083 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-17T21:07:00.000+03:00", "crawled": "2018-04-17T21:23:32.012+03:00", "highlightTitle": ""}